These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8683246)

  • 1. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
    Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
    J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.
    Sanchez E; Chacon I; Plaza MM; Muñoz E; Cruz MA; Martinez B; Lopez L; Martinez-Montero JC; Orradre JL; Saez AI; Garcia JF; Piris MA
    J Clin Oncol; 1998 May; 16(5):1931-9. PubMed ID: 9586912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
    Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
    Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
    Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
    J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
    Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
    Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas.
    Pagnano KB; Silva MD; Vassallo J; Aranha FJ; Saad ST
    Acta Haematol; 2002; 107(1):29-34. PubMed ID: 11818669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
    Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
    Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
    Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
    Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
    Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
    J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
    Huebner-Chan D; Fernandes B; Yang G; Lim MS
    Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.
    Camacho FI; Mollejo M; Mateo MS; Algara P; Navas C; Hernández JM; Santoja C; Solé F; Sánchez-Beato M; Piris MA
    Am J Surg Pathol; 2001 Oct; 25(10):1268-76. PubMed ID: 11688461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival.
    Fernández-Vázquez A; Rodríguez-Peralto JL; Martínez MA; Platón EM; Algara P; Camacho FI; López-Ríos F; Zarco C; Sánchez-Yus E; Fresno MF; Barthe L; Aliaga A; Fraga M; Forteza J; Oliva H; Piris MA
    Am J Surg Pathol; 2001 Mar; 25(3):307-15. PubMed ID: 11224600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
    Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.